article thumbnail

Provention faces delay in FDA review of diabetes prevention antibody

pharmaphorum

The issues are holding up discussions between the agency and company about labeling and post-marketing requirements for teplizumab, and are concentrated around the pharmacokinetics data for the antibody, and whether it is comparable to the drug that its original developer Eli Lilly entered into clinical trials.

article thumbnail

Self-injecting pill could offer oral administration for monoclonal antibodies, insulin and other drugs

BioPharma Reporter

A new type of self-injecting capsule could deliver medications at comparable levels to those given via injection, according to a preclinical study.

Insulin 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Provention’s Tzield can delay type 1 diabetes. But will it reach all patients?

Pharmaceutical Technology

Hailed as a breakthrough, Tzield’s approval marks the first of its kind to be introduced since the discovery of insulin, which won the 1923 Nobel Prize in the category of Physiology or Medicine. These therapies work by reprogramming the immune system, preventing it from attacking and eradicating insulin-producing cells in the pancreas.

Insulin 246
article thumbnail

RZ-358 by Rezolute for Hyperinsulinemia: Likelihood of Approval

Pharmaceutical Technology

The drug candidate is a fully human monoclonal antibody which is administered through intravenous route as a solution. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.

Insulin 100
article thumbnail

RZ-358 by Rezolute for Hyperinsulinemia: Likelihood of Approval

Pharmaceutical Technology

The drug candidate is a fully human monoclonal antibody which is administered through intravenous route as a solution. It is a fully human negative allosteric selective insulin receptor modulator (SIRMs) antibody derived from the XMet platform. It was also under development for the treatment of insulinomas.

Insulin 100
article thumbnail

Tzield Gets FDA Nod to Become First Approved Drug to Delay Onset of Type 1 Diabetes

XTalks

Type 1 diabetes, also known as insulin-dependent or juvenile diabetes, is an autoimmune disease that occurs when the body is unable to make enough insulin due to destruction of the beta insulin-producing cells in the pancreas. In the US, it is estimated that 1.45 million people are currently living with type 1 diabetes.

Insulin 97
article thumbnail

Sanofi unveils global health brand for medicines supply

Pharmaceutical Technology

Through the Impact brand, which comprises insulin, glibenclamide and oxaliplatin among others, the company will supply its 30 medicines in 40 lower-income countries in the world. The post Sanofi unveils global health brand for medicines supply appeared first on Pharmaceutical Technology.

Branding 147